Wall Street Analysts Predict a 44.79% Upside in Arcutis Biotherapeutics (ARQT): Here's What You Should Know

Arcutis Biotherapeutics (ARQT) is currently trading at $15.63, with Wall Street analysts projecting a mean price target of $22.63, implying a 44.8% upside. While the article cautions against relying solely on analyst price targets, it highlights a more robust indicator for ARQT's potential upside: significant upward revisions in earnings estimates. The Zacks Consensus Estimate for the current year has increased 21.2% over the last 30 days, with all revisions being positive, and the stock holds a Zacks Rank #2 (Buy), suggesting a strong basis for near-term appreciation.

Analysis

Arcutis Biotherapeutics (ARQT), closing at $15.63, presents a dual-signal scenario for investors. On one hand, Wall Street analysts have set a mean price target of $22.63, implying a significant 44.8% upside, with a range from $18.00 to $29.00. However, the article correctly cautions that analyst price targets can be unreliable and are often overly optimistic. The more compelling bullish indicator for ARQT is the substantive positive trend in earnings estimate revisions, which has a stronger empirical correlation with near-term stock performance. Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 21.2%, driven by three upward revisions and no downward revisions. This strong analyst agreement on improving earnings prospects is further corroborated by the stock's Zacks Rank #2 (Buy), placing it in the top 20% of over 4,000 ranked companies and suggesting a fundamentally driven potential for appreciation beyond its modest 1.3% gain over the past four weeks.

Key Decisions for Investors

• Investors should prioritize the 21.2% upward revision in the current year's consensus earnings estimate as a more reliable indicator of near-term potential than the headline analyst price targets.
• The combination of unanimous positive earnings estimate revisions and a Zacks Rank #2 (Buy) provides a strong rationale for considering a long position or adding to an existing one.
• Given the forward-looking nature of estimate revisions, it is crucial to monitor the company's next earnings release for fundamental results that validate the recent surge in analyst optimism.